Prognostic significance of the immunohistochemical staining of cleaved caspase-3, an activated form of caspase-3, in gliomas

Clinical Cancer Research

Volumn 13, Issue 13, 2007, Pages 3868-3874

  Kobayashi, Tatsuya ^a,b   Masumoto, Junya ^a   Tada, Tsuyoshi ^b   Nomiyama, Tetsuo ^a   Hongo, Kazuhiro ^b   Nakayama, Jun ^a  

^a SHINSHU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b SHINSHU UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3;

ADOLESCENT; ADULT; AGED; APOPTOSIS; ARTICLE; CHILD; CONFIDENCE INTERVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME ACTIVATION; FEMALE; GLIOBLASTOMA; GLIOMA; GLIOMA CELL; HAZARD RATIO; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; KAPLAN MEIER METHOD; LOG RANK TEST; MAJOR CLINICAL STUDY; MALE; PERFORMANCE; PRIORITY JOURNAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; PROTEIN DEGRADATION; RETROSPECTIVE STUDY; SURVIVAL; SURVIVAL TIME; WORLD HEALTH ORGANIZATION;

ADOLESCENT; ADULT; BRAIN NEOPLASMS; CASPASE 3; CHILD; CHILD, PRESCHOOL; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOMA; HUMANS; INFANT; MALE; MIDDLE AGED; PROGNOSIS;

EID: 34447115084     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-06-2730     Document Type: Article

References (30)

1. Hoshino T, Ahn D, Prados MD, Lamborn K, Wilson CB. Prognostic significance of the proliferative potential of intracranial gliomas measured by bromodeoxyuridine labeling. Int J Cancer 1993;53:550-5.
2. Ganju V, Jenkins RB, O'Fallon JR, et al. Prognostic factors in gliomas. A multivariate analysis of clinical, pathologic, flow cytometric, cytogenetic, and molecular markers. Cancer 1994;74:920-7.
3. Nelson JS, Tsukada Y, Schoenfeld D, Fulling K, Lamarche J, Peress N. Necrosis as a prognostic criterion in malignant supratentorial, astrocytic gliomas. Cancer 1983;52:550-4.
4. Burger PC, Vogel FS, Green SB, Strike TA. Glioblastoma multiforme and anaplastic astrocytoma. Pathologic criteria and prognostic implications. Cancer 1985;56:1106-11.
5. Burger PC, Green SB. Patient age, histologic features, and length of survival in patients with glioblastoma multiforme. Cancer 1987;59:1617-25.
6. Daumas-Duport C, Scheithauer B, O'Fallon J, Kelly P. Grading of astrocytomas. A simple and reproducible method. Cancer 1988;62:2152-65.
7. Paulus W, Peiffer J. Intratumoral histologic heterogeneity of gliomas. A quantitative study. Cancer 1989;64:442-7.
8. Williams GT. Programmed cell death: apoptosis and oncogenesis. Cell 1991;65:1097-8.
9. Wyllie AH. Apoptosis. Br J Cancer 1993;67:205-8.
10. Migheli A, Cavalla P, Marino S, Schiffer D. A study of apoptosis in normal and pathologic nervous tissue after in situ end-labeling of DNA strand breaks. J Neuropathol Exp Neurol 1994;53:606-16.
11. Nicholson DW, Ali A, Thornberry NA, et al. Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis. Nature 1995;376:37-43.
12. Krajewska M, Wang HG, Krajewski S, et al. Immunohistochemical analysis of in vivo patterns of expression of CPP32 (caspase-3), a cell death protease. Cancer Res 1997;57:1605-13.
13. Zou H, Henzel WJ, Liu X, Lutschg A, Wang X. Apaf-1, a human protein homologous to C. elegans CED-4, participates in cytochrome c-dependent activation of caspase-3. Cell 1997;90:405-13.
14. Núñez G, Benedict MA, Hu Y, Inohara N. Caspases: the proteases of the apoptotic pathway. Oncogene 1998;17:3237-45.
15. Nakagawara A, Nakamura Y, Ikeda H, et al. High levels of expression and nuclear localization of interleukin-1b converting enzyme (ICE) and CPP32 in favorable human neuroblastomas. Cancer Res 1997;57:4578-84.
16. Donoghue S, Baden HS, Lauder I, Sobolewski S, Pringle JH. Immunohistochemical localization of caspase-3 correlates with clinical outcome in B-cell diffuse large-cell lymphoma. Cancer Res 1999;59:5386-91.
17. Hsia JY, Chen CY, Chen JT, et al. Prognostic significance of caspase-3 expression in primary resected esophageal squamous cell carcinoma. Eur J Surg Oncol 2003;29:44-8.
18. Takata T, Tanaka F, Yamada T, et al. Clinical significance of caspase-3 expression in pathologic-stage I, nonsmall-cell lung cancer. Int J Cancer 2001;96 Suppl:54-60.
19. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
20. Cox DR. Regression models and life tables. J R Sfut Soc (B) 1972;34:187-220.
21. Gown AM, Willingham MC. Improved detection of apoptotic cells in archival paraffin sections: immunohistochemistry using antibodies to cleaved caspase 3. J Histochem Cytochem 2002;50:449-54.
22. Coons SW, Johnson PC, Scheithauer BW, Yates AJ, Pearl DK. Improving diagnostic accuracy and interobserver concordance in the classification and grading of primary gliomas. Cancer 1997;79:1381-93.
23. Scott JN, Rewcastle NB, Brasher PM, et al. Which glioblastoma multiforme patient will become a long-term survivor? A population-based study. Ann Neurol 1999;46:183-8.
24. Laws ER, Parney IF, Huang W, et al. Surv ival following surgery and prognostic factors for recently diagnosed malignant glioma: data from the Glioma Outcomes Project. J Neurosurg 2003;99:467-73.
25. McLendon RE, Halperin EC. Is the long-term survival of patients with intracranial glioblastoma multiforme overstated? Cancer 2003;98:1745-8.
26. Yomo S, Tada T, Hirayama S, et al. A case report and review of the literature. J Neurooncol 2007;81:209-16.
27. Yuan J, Shaham S, Ledoux S, Ellis HM, Horvitz HR. The C. elegans cell death gene ced-3 encodes a protein similar to mammalian interleukin-1 β-converting enzyme. Cell 1993;75:641-52.
28. Steller H. Mechanisms and genes of cellular suicide. Science 1995;267:1445-9.
29. Depraetere V, Golstein P. Dismantling in cell death: molecular mechanisms and relationship to caspase activation. Scand J Immunol 1998;47:523-31.
30. Kondo S, Tanaka Y, Kondo Y, et al. Retroviral transfer of CPP32β gene into malignant gliomas in vitro and in vivo. Cancer Res 1998;58:962-7.